S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   444.83 (+0.00%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
NASDAQ:RPRX

Royalty Pharma (RPRX) Stock Price, News & Analysis

$30.59
+0.14 (+0.46%)
(As of 09:47 AM ET)
Today's Range
$30.49
$30.68
50-Day Range
$27.71
$31.33
52-Week Range
$25.92
$37.31
Volume
124,497 shs
Average Volume
2.64 million shs
Market Capitalization
$18.28 billion
P/E Ratio
16.19
Dividend Yield
2.75%
Price Target
$52.25

Royalty Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.6% Upside
$52.25 Price Target
Short Interest
Healthy
3.34% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.86mentions of Royalty Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$7.69 M Sold Last Quarter
Proj. Earnings Growth
9.74%
From $3.90 to $4.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Finance Sector

4th out of 863 stocks

Pharmaceutical Preparations Industry

3rd out of 436 stocks

RPRX stock logo

About Royalty Pharma Stock (NASDAQ:RPRX)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Stock Price History

RPRX Stock News Headlines

Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
RPRX Dec 2024 17.500 call
RPRX Oct 2024 40.000 put
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Goldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Royalty Pharma Reports Q4 and Full Year 2023 Results
Royalty Pharma Reports Q4 and Full Year 2023 Results
Royalty Pharma's Earnings: A Preview
See More Headlines
Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Ex-Dividend for 3/15 Dividend
2/15/2024
Dividend Payable
3/15/2024
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Finance
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:RPRX
CUSIP
76028H20
Fax
N/A
Employees
51
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$52.25
High Stock Price Target
$60.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+71.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$1.13 billion
Pretax Margin
72.20%

Debt

Sales & Book Value

Annual Sales
$2.36 billion
Cash Flow
$4.59 per share
Book Value
$16.88 per share

Miscellaneous

Free Float
485,595,000
Market Cap
$18.19 billion
Optionable
Optionable
Beta
0.45

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 59)
    Founder, Chairman of the Board & CEO
  • Mr. Terrance P. Coyne
    Executive VP & CFO
  • Mr. George Wingate Lloyd (Age 65)
    Executive VP of Investments & Chief Legal Officer
    Comp: $4.35M
  • Mr. Christopher Hite (Age 57)
    Vice Chairman & Executive VP
    Comp: $4.35M
  • Dr. Marshall Urist M.D.
    Ph.D., Executive VP and Head of Research & Investments
  • Mr. Arthur R. McGivern J.D.
    Executive Vice President of Investments & General Counsel
  • Mr. Ashwin Pai M.D.
    Executive Vice President of Investments
  • Ms. Kristin Stafford (Age 41)
    Senior VP & Chief Accounting Officer
  • Mr. Eric Schneider
    Senior VP & Chief Technology Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 54)
    Executive VP of Investments & Chief Scientific Officer
    Comp: $3.4M

Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Royalty Pharma was last updated on Wednesday, March 27, 2024 at 11:06 PM.

Pros

Here are some ways that investors could benefit from investing in Royalty Pharma plc:

  • Royalty Pharma plc operates as a buyer of biopharmaceutical royalties, providing a unique investment opportunity in the biopharmaceutical industry.
  • The company collaborates with innovators from various sectors, including academic institutions, research hospitals, and biotechnology companies, enhancing its potential for growth and innovation.
  • Identifying, evaluating, and acquiring royalties on biopharmaceutical therapies can lead to a diversified revenue stream for the company, potentially reducing investment risk.
  • Recent positive developments in the biopharmaceutical industry have increased the demand for innovative therapies, potentially benefiting Royalty Pharma plc's portfolio.
  • Considering the current stock price and market trends, investing in Royalty Pharma plc may offer a favorable entry point for investors seeking exposure to the biopharmaceutical sector.

Cons

Investors should be bearish about investing in Royalty Pharma plc for these reasons:

  • Market volatility and regulatory changes in the biopharmaceutical industry can impact the company's revenue streams and profitability.
  • Competition in the biopharmaceutical royalty market may pose challenges for Royalty Pharma plc in acquiring lucrative royalties and maintaining growth.
  • Fluctuations in biopharmaceutical research and development trends could affect the company's ability to identify and acquire royalties on successful therapies.
  • External economic factors, such as interest rate changes or global market conditions, may influence the company's financial performance and stock valuation.
  • Investors should carefully assess the company's financial reports, market positioning, and industry outlook before making investment decisions in Royalty Pharma plc.

RPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings
or view top-rated stocks.

What is Royalty Pharma's stock price target for 2024?

4 brokerages have issued 1 year price targets for Royalty Pharma's shares. Their RPRX share price targets range from $42.00 to $60.00. On average, they anticipate the company's stock price to reach $52.25 in the next year. This suggests a possible upside of 71.6% from the stock's current price.
View analysts price targets for RPRX
or view top-rated stocks among Wall Street analysts.

How have RPRX shares performed in 2024?

Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have increased by 8.4% and is now trading at $30.45.
View the best growth stocks for 2024 here
.

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPRX earnings forecast
.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) issued its earnings results on Thursday, February, 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.03 by $0.12. The biopharmaceutical company earned $736 million during the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a trailing twelve-month return on equity of 26.93% and a net margin of 48.22%.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Friday, January 19th. Investors of record on Friday, February 16th will be given a dividend of $0.21 per share on Friday, March 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date is Thursday, February 15th. This is a boost from the stock's previous quarterly dividend of $0.20.
Read our dividend analysis for RPRX
.

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 2.78%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.36%), Vanguard Group Inc. (6.36%), Baillie Gifford & Co. (2.94%), Viking Global Investors LP (1.69%), Norges Bank (0.71%) and Legal & General Group Plc (0.49%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne.
View institutional ownership trends
.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners